ΔNp63α promotes Bortezomib resistance via the CYGB–ROS axis in head and neck squamous cell carcinoma

by Song, X., Zhang, C., Zhang, D., Zheng, H., Zhou, P., Zhu, M.
Published 2022

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics

by Anderson, L.D., Jr, Beksac, M., Corso, A., Dimopoulos, M., Dürig, J., Engelhardt, M., Galli, M., Grote, L., Jenner, M., Jiang, R., Kanate, A.S, Larocca, A., Liberati, A.M, Lindsay, J., Moreau, P., Oriol, A., Pavic, M., Peluso, T., Richardson, P.G, Robak, P., Rodriguez-Otero, P., Salomo, M., Schjesvold, F., Sonneveld, P., Vural, F., Weisel, K., White, D., Yagci, M.
Published 2022